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LABORATORY INVESTIGATION
Urinary C3dg and C5b-9 indicate active immune disease in
human membranous nephropathy
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Urinary C3dg and C5b-9 indicate active immune disease in human
membranous nephropathy. We have measured complement activation
markers, C3dg and C5b-9 in plasma and urine from patients with
idiopathic membranous nephropathy and IgA nephropathy. There was
no significant difference in levels of plasma C5b-9 between the patient
groups. However, high plasma concentrations of C3dg were associated
significantly with IgA nephropathy with 45% of patients having levels
over 25 U/mI (P < 0.001). High concentrations of urinary C3dg and
C5b-9 were associated significantly with membranous nephropathy
(43% and 43% of the patient group, respectively) compared to patients
with IgA nephropathy (10% and 0%, respectively, P < 0.001). In a
retrospective analysis of 31 patients with membranous nephropathy,
66% of patients with high initial urinary C5b-9 showed an unstable
clinical course compared to 18% of patients with initially absent or low
C5b-9 (P < 0.001). We suggest that high urinary C5b-9 identifies those
patients with a membranous lesion which retains an active immunolog-
ical component contributing to the pathology of progressive glomerular
damage.
The pathological description of membranous nephropathy
(MN) which includes granular deposition of IgG and C3 along
the subepithelial surface of the glomerular basement membrane
(GBM) supports the hypothesis of an immune pathogenesis [I].
Furthermore, the study of animal models that mimic the histo-
pathology of human membranous nephropathy has enabled the
development of a conceptual framework to link structural
components of the glomerulus with the deposition of antibody,
the activation of complement and the induction of proteinuria.
For proteinuria to occur in the passive model of Heymann
nephritis [2J, it is necessary that IgG antibodies (anti-Fxla) bind
to intrinsic glomerular epithelial cell surface antigens, and
deposit in the subepithelial site so that complement is activated
and production of the terminal complement complex, C5b-9
ensues. Clearly in this experimental acute lesion there is a
direct relationship between an active immune mechanism and
proteinuria. It has recently been shown in a chronic animal
model of membranous nephropathy (autologous immune com-
plex nephritis in the rat), that urinary excretion of C5b-9
parallels active immunologic disease whereas proteinuria does
not [3].
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In human disease, the proteinuria usually continues for
months or years, and it is not known if this proteinuria
represents continuing immunological damage. Sequential stud-
ies in patients with drug-induced membranous nephropathy
have identified patients with continuing proteinuria long after
the offending agent has been withdrawn [4, 5]. Thus, in any
patient with membranous nephropathy, the proteinuria may be
the result of a recent or distant insult and could be the product
of any combination of factors including an active immune
process, residual damage from previous injury, or progressive
haemodynamic changes in the glomerulus. If immunoactive
drugs do have a role in the therapy of MN, it would appear
essential to identify those patients who show evidence of an
active immunological insult.
We have, therefore, investigated the complement system as a
means of assessing activity of the underlying immune lesion in
human MN. We have previously shown that the C3 derived
product, C3dg, can be detected at high levels in the urine of
membranous nephropathy patients [6]. We now report a study
of early and terminal complement activation markers, C3dg and
C5b-9, respectively, in urine and plasma of patients with
idiopathic membranous nephropathy. The results are compared
to those in patients with IgA nephropathy, another glomerular
lesion involving complement deposition, where the immunolog-
ical insult appears to be predominantly within the mesangiurn as
opposed to the subepithelial site. We have carried out a
retrospective analysis of the clinical course of 31 patients with
MN over an average period of 4.6 years and have correlated
outcome with initial levels of urinary C5b-9 and C3dg.
Methods
The patient groups consisted of 44 individuals with biopsy-
proven idiopathic membranous nephropathy (31 male, 13 fe-
male, mean age 52 years) and 40 patients with biopsy-proven
IgA nephropathy, (32 male, 8 female, mean age 42 years). C3dg
results were obtained on all individuals. C5b-9 levels were
measured on 34 plasma and 35 urine samples from MN patients,
and 29 plasma and 27 urine samples from IgA patients. Twenty-
five laboratory workers (17 male, 8 female, mean age 41 years)
were used as normal controls, and 20 patients with significant
proteinuria (9 with focal segmental glomerulosclerosis, 9 with
diabetic nephropathy and 2 with amyloid) were included as a
proteinuric control group for C5b-9 assays.
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Blood was taken by venipuncture, collected into EDTA and
kept at 4°C. The samples were centrifuged at 2500 rpm for 10
minutes and aliquots of the plasma were stored at —70°C.
Freshly voided urine was collected into EDTA at 4°C, and
aliquots stored at —70°C. The urine samples were assayed for
C3dg, C5b-9 and creatinine content. Twenty-four-hour urine
collections were analyzed for protein and creatinine content.
No patient was receiving immunoactive drugs at the start of
this study. During the period of observation some patients
received immunosuppressive therapy. This consisted of a pulse
of methyl prednisolone, 1 g intravenously daily for five days,
followed by alternate-day oral prednisolone, tapering over 8
months [7].
ELISA for C5b-9
Sensitive immunoassays for C5b-9 have employed a mono-
clonal antibody to a neo-epitope on C9 as the capture reagent
together with an antibody recognizing either CS [8], C6 [3J, or
C9 19]. We have quantitated C5b-9 using an enhanced chemilu-
minescence sandwich immunoassay employing the IgG fraction
from ascitic fluid containing antibody to C9 neo-antigen [101,
which is reported to bind both SC5b-9 and C5b-9,and the IgG
fraction from a rabbit anti-C7 serum (Serotec). Combinations of
anti-C9 neo-epitope antibody with anti-CS, anti-C6, anti-C8,
and anti-C9 were also evaluated, and the chosen combination
produced the optimum signal to noise ratio when assaying
partially purified C5b-9. The IgG fractions were isolated by
three cycles of ammonium sulfate precipitation (40% final
concentration). The anti-C7 antibody was biotinylated with
NHS-Biotin [11]. The IgG monoclonal antibody to a C9 neo-
epitope was coated at 10 g/ml in 0.1 M carbonate buffer, pH 9.6
onto-microFluor multiwell plates (Dynatech) overnight at 4°C.
The plates were washed twice in PBS and blocked with 1% BSA
in PBS for one hour. After washing twice in PBS-Tween 0.05%,
a 1/20 dilution of plasma or urine was added to the wells and
incubated overnight at 4°C. After washing three times in PBS-
Tween, biotinylated anti-C7 was added (5 g/ml) and left for
four hours. After further washing, avidin-peroxidase (Sigma)
diluted 1/200 was added for two hours. The plates were washed
five times in PBS-Tween, and then enzyme substrate (Amerlite
reagent, Amersham mt.) was added and the chemiluminescence
was detected using a luminometer (Amersham mt.). A standard
containing SC5b-9 was prepared by incubating fresh human
serum with 10 mg/mI zymosan (Sigma) at 37°C for four hours.
The serum was clarified by centrifugation at 10,000 g for 30
minutes and stored in aliquots at —70°C, Dilutions of the
standard were used to construct a linear standard curve of
luminescence over the range of 25 to 100 (background <5), from
which arbritrary units of C5b-9 were read (range 3 to 100 units).
ELISA for C3dg
An ELISA assay for C3dg was developed using rabbit
anti-C3d (Dako Ltd) coated onto 96-well microtiter plates
(Dynatech) at a 1/500 dilution in 0.1 M sodium carbonate buffer,
pH 9.6, overnight at 4°C. Plates were washed in PBS-Tween
0.05%, blocked and rewashed as described above. Plasma,
urine and standards were pretreated with polyethylene glycol
6000 to remove high molecular weight D epitopes present on
native C3 [12J. A standard C3dg preparation was made by
incubating human serum with inulin 10 mg/mI at 37°C for 24
hours. The serum was centrifuged at 10000 g for 30 minutes and
stored in aliquots at —70°C. Standards and test samples were
added to anti-C3dg coated plates. After two hours the plates
were washed four times with PBS-Tween and then peroxidase
conjugated anti-C3dg (Dako Ltd) diluted to 1/300 was added and
left for a further two hours. Following the final three washes
with PBS-Tween, the plates were developed with 1 mM ABTS
(2,2, azinobis-3-ethylbenzthiazoline suiphonic acid, Sigma) in
citrate, phosphate buffer pH 5.0 containing 0.1 m hydrogen
peroxide. The absorbance at 420 nm was measured using a
Titertek Multiskan plate reader (Flow Labs). Dilutions of the
standard were used to construct a linear standard curve over an
optical density range of 0.23 to 1.30 (background absorbance
0.02) from which arbritrary units of C3dg were read, (range 8 to
250 units). For urine samples, the C3dg and C5b-9 concentra-
tions were related to the creatinine content of the freshly voided
sample [13], that is, C3dg units (or C5b-9 units)/ml divided by
creatinine concentration mg/mI.
Results
Detection of C5b-9
In plasma and urine from normal controls, the C5b-9 complex
was undetectable, although it was present in plasma and urine
from patients, (Fig. 1). There was no significant difference in
plasma C5b-9 levels between the patients with membranous
nephropathy and IgA nephropathy, (chi-square test, P> 0.1,
Table 1). All patients with IgA nephropathy and greater than 5
units of plasma C5b-9 had macroscopic hematuria. The urine
C5b-9 concentrations in the membranous patients were ele-
vated with 43% of the group having values over S units
compared to none of the IgA nephropathy group (chi-square
test, P < 0.001, Table 1).
Detection of C3dg
In urine from controls, C3dg was undetectable, (Fig. 2). Low
levels of C3dg could be identified in normal plasma. Patients
with IgA nephropathy showed significantly higher plasma levels
of C3dg with 45% of patients having levels >25 units compared
to plasma levels in patients with membranous nephropathy
where only 9% of patients had levels >25 units, (P < 0.001,
Table 2). Interestingly, of the 20 patients with IgA nephropathy
who had macroscopic hematuria or high urinary red cell counts,
18 had >25 units of plasma C3dg. None of the 20 patients with
normal urine red cell counts had >25 units of plasma C3dg (P <
0.001). The inverse situation was observed with C3dg in urine
with 43% of patients with membranous nephropathy having
>25 units compared to 10% of patients with IgA nephropathy,
(P < 0.001, Table 2).
Urinary complement products in membranous patients
The observation that patients with membranous nephropathy
have raised levels of urinary C3dg and C5b-9 suggested the
possibility of an artifactual activation of complement in the
urine of these patients. However, no correlation between
urinary C3dg and C5b-9 concentrations was found in patients (r
= 0.128, Spearman rank correlation coefficient, P > 0.05).
Furthermore, in an analysis of urine from 20 patients with other
nephropathies with similar levels of proteinuria (mean = 7.83 ±
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Patients
Plasma C5b-9 Un
>5
ne C5b-9
units <5>5 units <5
MN 6 (18%) 28 15 (43%) 20
IgA 5 (17%) 24 0 (0%) 27
Chi-square test P> 0.1 P < 0.001
5.74 g/24 hr, range = 2.01 to 20.05 g/24 hr), C5b-9 was detected
in only one patient (with FSGS).
Urine C5b-9 levels showed no correlation with proteinuria in
membranous nephropathy (r = 0.22, Spearman rank correlation
coefficient, P > 0.05), whereas urine C3dg was positively
correlated with proteinuria (r = 0.55, Spearman rank correla-
tion coefficient, P = 0.001, data not shown).
The association of urinary C5b-9, C3dg or proteinuria with
the subsequent clinical course of disease was analyzed in 31
patients over a mean time period of 4.6 years. Patients were
categorized as having an unstable clinical course if they devel-
oped end-stage renal failure, or if their serum creatinine in-
creased by more than 30%, to over 200 mol/1iter. Sixty-six
percent (6/9) of patients with high urinary C5b-9 subsequently
showed an unstable clinical course compared to 18% (4/22) of
patients with absent or low C5b-9, (Fishers exact test, P < 0.01,
Table 3). Similarly, 66% (8/12) of patients with a high urinary
C3dg had an unstable course compared to 11% (2/19) of patients
with absent or low C3dg, (P < 0.01, Table 3). Comparison of
patients with high (>5 g/24 hr) or low (<5 g/24 hr) proteinuria
failed to show a significant association with an unstable clinical
course (P > 0.05) in this cohort of patients (data not shown).
Discussion
The complement system plays an important role in infectious
disease and in the pathogenesis of a wide variety of immune
mediated inflammatory diseases. Methods have been developed
allowing detection of activated components of the complement
system in human tissues [10], serum [14], synovial fluid [9] CSF
[15] and urine [6]. Elevated plasma C5b-9 levels are reported in
the active phase of SLE nephritis and in some infections [14].
Increased levels of C5b-9 are also reported in cerebrospinal
fluid of patients with inflammation of the central nervous
system and in synovial fluid of patients with rheumatoid arthri-
tis [15].
In human membranous nephropathy, glomerular deposition
of both C3 (indicating early component activation) [16], and
C5b-9 (indicating terminal component activation) [10], is well
documented. We now report the presence of high levels of both
these complement products in the urine but not in the plasma of
patients with MN. Conversely, high levels of C3dg were found
in the plasma but not in the urine in patients with IgA nephrop-
athy. Although complement activation is thought to be an
essential part of the immune pathogenesis of these diseases,
they differ in the intrarenal site of immune complex deposition
and complement activation. In IgA nephropathy, with mesan-
gial complement deposition, C3dg (Mr = 43 KD) would have
immediate access to the capillary lumen and could be filtered
through the basement membrane, whereas C5b-9 (Mr = >1,000
KD) is likely to be retained in the circulation. Indeed, it has
been shown in rats made proteinuric with puromycin that
preformed C5b-9 injected intravenously remains in the vascular
compartment, and is not detected in the urine [171. In membra-
nous nephropathy, where complement activation takes place in
the subepithelial site, both products would have unhindered
access to the urinary space but may be prevented from entering
the vascular circulation by the transmembrane flux of fluid.
Additionally, for C5b-9, the basement membrane would prevent
access to the capillary lumen due to the molecular size of the
complement complex.
C5b-9 was only detected in 1/20 control patients with signif-
icant proteinuria, which argues against the complex being
formed spontaneously by artifactual C3 activation in the renal
tubules or bladder. Furthermore, it has been demonstrated that
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Table 1. Numbers of MN and IgA patients with high and low levels
of plasma and urine C5b-9
Fig. 1. Plasma (units/mi) and urine (units/mg
creatinine) concentrations of C5b-9 in patients
with membranous nephropathy (MN), IgA
nephropathy (igA) and normal controls.
Symbols are: (•) 1 patient; (A) 5 patients.
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Table 2. Numbers of MN and IgA patients with high and low Ic
of plasma and urine C3dg
vels
Patients
Plasma C3dg Urine C3dg
>25 units <25 >25 units <25
MN 4 (9%) 40 19 (43%) 25
IgA 18 (45%) 22 4 (10%) 36
Chi-square test P < 0.001 P < 0.001
even with extensive C3 activation, there is a relative ineffi-
ciency in formation of the terminal complex due to a dissocia-
tion at the level of CS convertase formation/CS cleavage and to
inefficient utilization of C5b [18].
In this cross sectional study, 57% of patients were positive
for urinary C5b-9. Of the 10 patients who showed an unstable
clinical course, 8 initially had urinary excretion of both C3dg
and C5b-9, and one had urinary C3dg detectable at the outset
and became positive for C5b-9 during the study. In only one
patient, who had C3dg, did we fail to detect urinary C5b-9
during the period of study. Thus, our observation is that urinary
excretion of C5b-9 is a common finding in human membranous
nephropathy, Furthermore, high levels of CSb-9 were associ-
ated significantly with a poor clinical outcome.
Subepithelial C5b-9 deposition occurs in both the passive
Heymann nephritis and the cationic antigen models of MN.
However, urinary C5b-9 excretion is unique to passive Hey-
mann nephritis [17, 19], where the initiating antigen is an
integral membrane component of the glomerular epithelial cell.
A mechanism for urinary C5b-9 excretion by the epithelial cell
has been proposed which involves selective retrieval of mem-
brane C5b-9 into intracellular membrane vesicles, and the
transport of these vesicles across the cell to promote exocytosis
of their contents into the urinary space [20]. The precise
relevance of this mechanism to the human disease remains
uncertain until antigen(s) are defined. Preliminary results sug-
gest that monitoring urinary C5b-9 in patients with membranous
Table 3. The number of MN patients with stable or unstable clinical
outcome related to initial urinary C5b-9 and urinary C3dg
Initial C5b-9 Initial C3dg
Clinical course >7 units <7 >25 units <25
Stable 3 18 4 17
Unstable 6 (66%) 4 (18%) 8 (66%) 2 (11%)
Fisher test P < 0.01 P < 0.01
nephropathy may identify those with an active immunological
disease and provide a means of assessing the efficacy of immune
modulating therapy [21]. Clearly, a prospective trial to monitor
excretion of C5b-9 during the course of MN and to study the
effects of treatment on CSb-9 expression is needed.
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